Fresenius Medical Care refines China strategy. Fresenius Medical Care stock costs EUR 39.60
Published on 10/03/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 25, 2026, Fresenius Medical Care announced refinements to its China commercial strategy in a company press release. At 10:13 a.m. CEST on October 3, 2026, Lang & Schwarz showed the stock at EUR 39.60 in weekend trading, unchanged from its EUR 39.60 close on October 2, 2026.
Weekend trading
The Lang & Schwarz bid was EUR 39.43 and the ask was EUR 39.77 at the recorded time. The company is listed on the Frankfurt Stock Exchange under ticker FME. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Fresenius Medical Care stock.
China portfolio strategy
Fresenius Medical Care said the strategy will place greater emphasis on a localized portfolio, locally relevant innovation and a focused go-to-market approach. The company plans to focus on in-center dialysis and critical-care technologies, discontinue local production and sales of the 4008A hemodialysis system, and exit its China peritoneal dialysis business while maintaining existing obligations. The changes are expected to result in approximately EUR 110 million of one-time costs, primarily related to impairment charges, scrappage and termination costs, recognized as a special item in the third quarter of 2026, according to the company release.
Cybersecurity statement
In a September 22, 2026 media statement, Fresenius Medical Care said it was investigating unauthorized access to a limited number of internal systems. The company said medical devices, patient care, manufacturing operations and business continuity had not been impacted, according to its statement.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
